Meric-Bernstam Funda, Rasmussen John C, Krishnamurthy Savitri, Tan I-Chih, Zhu Banghe, Wagner Jamie L, Babiera Gildy V, Mittendorf Elizabeth A, Sevick-Muraca Eva M
Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA ; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA ; These authors contributed equally to this work.
Center for Molecular Imaging, The Brown Foundation Institute of Molecular Medicine at the University of Texas Health Science Center at Houston, Houston, TX 77030 USA ; These authors contributed equally to this work.
Biomed Opt Express. 2013 Dec 13;5(1):183-96. doi: 10.1364/BOE.5.000183.
As part of a proof-of-concept study for future delivery of targeted near-infrared fluorescent (NIRF) tracers, we sought to assess the delivery of micrograms of indocyanine green to all the axillary lymph nodes following intraparenchymal breast injections and intradermal arm injections in 20 subjects with advanced breast carcinoma and undergoing complete axillary lymph node dissection. Lymphatic vessels and nodes were assessed in vivo. Ex vivo images demonstrated that 87% of excised lymph nodes, including 81% of tumor-positive lymph nodes, were fluorescent. Future clinical studies using microdose amounts of tumor-targeting NIRF contrast agents may demonstrate improved surgical intervention with reduced morbidity.
作为未来靶向近红外荧光（NIRF）示踪剂递送概念验证研究的一部分，我们试图评估在20例晚期乳腺癌且即将接受完整腋窝淋巴结清扫术的受试者中，经乳腺实质内注射和皮内手臂注射后，微克级吲哚菁绿向所有腋窝淋巴结的递送情况。对淋巴管和淋巴结进行了体内评估。离体图像显示，87%的切除淋巴结呈荧光，其中包括81%的肿瘤阳性淋巴结。未来使用微剂量肿瘤靶向NIRF造影剂的临床研究可能会显示手术干预得到改善，且发病率降低。
